Articles tagged with Cancer Medication
Researchers have produced detailed descriptions of human folate receptor proteins, aiding in the design of new drugs that can target cancer cells without harming healthy ones. The findings could lead to effective treatments for ovarian cancers and inflammatory diseases such as rheumatoid arthritis.
Scientists have discovered a new biomarker that predicts how well cancer patients respond to cancer drugs. The biomarker, linked to PRL-3 protein levels, identifies patients who are most likely to benefit from existing anti-cancer treatments, reducing healthcare costs and potentially saving lives.
Researchers found that IL-17 signaling in tumor-infiltrating T cells encourages resistance to VEGF-blockade in mouse models. Inhibiting IL-17 with monoclonal antibodies may improve clinical efficacy of VEGF-targeting drugs, a potential new strategy for cancer therapy.
A noninvasive colorectal screening approach like fecal immunochemical tests (FIT) may be more effective than colonoscopy in prompting participation among underserved populations. Organized mailing campaigns offering two colorectal cancer tests increased screening rates as much as threefold among uninsured patients.
Researchers at Columbia University Irving Medical Center have identified 18 new genes responsible for glioblastoma multiforme, the most common and aggressive form of brain cancer. About 15 percent of patients may be eligible for personalized treatment with existing drugs used in other cancers.
UC Davis researchers discover how cancer chemotherapy agent Topotecan acts on gene causing Angelman syndrome, a rare neurodevelopmental disorder. The study highlights the significance of epigenetics in understanding both rare and common neurodevelopmental disorders.
Researchers found cancer cells can reverse replication forks using 'fork reversal' repair after DNA damage caused by topoisomerase I inhibitors. This process is controlled by proteins PARP and RECQ1, which could be targeted for effective treatment with lower toxic side effects.
A population-based study found that current use of calcium-channel blockers for 10 or more years was associated with a higher risk of ductal and lobular breast cancer. The relationship did not vary based on the type of calcium-channel blockers used, with other antihypertensive medications showing no increased risk.
A new study by Fred Hutchinson Cancer Research Center scientists found that long-term use of calcium-channel blockers increases the risk of invasive ductal and lobular cancers. The study suggests alternative options for managing hypertension may be beneficial for reducing breast cancer risk.
UPCI researchers discovered that targeting 'cell sleep' can kill a larger fraction of cancer cells, increasing the effectiveness of cancer drugs. This finding has implications for gastrointestinal stromal tumors (GISTs), which are often treated with targeted therapy drug imatinib.
Researchers have discovered how an experimental drug can completely eradicate human lymphoma in mice after just five doses by gumming up the powerful master regulatory transcription factor Bcl6. The study provides a promising new strategy to treat diffuse large B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma.
Researchers at Scripps Research Institute have successfully synthesized a highly complex, plant-derived compound called ingenol, which has long been of interest for its potential in treating various cancers. The efficient chemical synthesis will enable scientists to investigate the therapeutic properties of ingenol derivatives and pote...
Researchers identified Skp2 inhibitor that blocks malignancy-promoting effects, shrinks tumors in preclinical studies. The compound suppresses prostate cancer stem cells, which play a role in cancer initiation and progression.
Researchers discovered a novel protein called ceramide-1 phosphate transport protein (CPTP), which regulates biologically active lipids and plays a role in cell signaling. The study sheds light on the cellular mechanisms contributing to diseases like cancer, asthma, and thrombosis.
Rapamycin treatment improved memory, reduced thyroid follicle size, and decreased cancer rates in older mice. However, its effects were age-independent, with similar benefits seen in young mice, suggesting a potential use for relieving some age-related conditions.
Scientists at Cancer Research UK have discovered a new molecule that prevents cancer cells from responding to low oxygen levels, targeting the master switch HIF-1. The researchers developed this approach using synthetic biology and testing over 3.2 million potential compounds.
Researchers discovered a function of PTEN that helps explain why certain therapies fail in many cancer patients. The finding increases understanding of molecular mechanisms and provides clues for individualizing therapy for patients with PTEN-deficient tumors.
A team led by Fred Hutchinson Cancer Research Center scientists is developing precision therapies that selectively kill cancer cells while sparing normal tissue. Using high-throughput screening, they aim to identify new genes to target that may be highly specific to each patient's tumor.
Researchers developed new compounds that mimic catestatin, a naturally used blood pressure regulator. The findings suggest these compounds could be used to control hypertension and potentially lead to new treatments for the disease.
Malpractice claims in primary care mainly stem from missed diagnoses of cancer, heart attack, and meningitis, with a substantial proportion of deaths attributed to these errors. Drug errors also account for a significant share of claims, although rates vary across countries.
Researchers at UCSF have discovered a way to indirectly target myc-driven tumors using an experimental drug that targets the mTOR protein. Clinical trials for this new treatment approach may soon be available for patients with myc-driven cancers.
Researchers have developed a promising new cancer treatment, PAC-1, which targets a cellular enzyme to spur cancer cells to self-destruct. The compound has shown safe and anti-cancer effects in cell culture, mouse models, and pet dogs with spontaneously occurring cancers.
Scientists at Nanyang Technological University (NTU) have developed a new technique called Cellular Thermal Shift Assay (CETSA) that can accurately determine if a drug has reached its target protein in the human body. This breakthrough method will help reduce the costly and time-consuming trial-and-error process of drug development.
Researchers have discovered novel compounds that fine-tune the activity of cells' protein-disposing machinery, which can help target solid tumors. These 'allosteric regulators' show promise as anti-cancer therapies without inducing drug resistance.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have identified specific types of intestinal bacteria that contribute to the development of lymphoma. These bacteria can be targeted with antibiotics to reduce cancer risk, while promoting protective bacteria through probiotics may also be effective.
Researchers generated a comprehensive list of cancer-specific genetic variations and made them available to the public. The extensive data set has the potential to dramatically enhance understanding of relationships between specific cancer-related genetic variations and drug response.
Recent studies have found chemotherapy-associated adverse neurological effects, including vascular complications and neuropathic pains. Chemotherapy triggers changes in ion channels on dorsal root ganglia, resulting in secondary changes that affect neurogenesis and plasticity.
Researchers have gained groundbreaking knowledge about proteases, enzymes that play a role in cancer cell development. The study reveals that proteases can bind to each other instead of just cleaving, which may lead to the development of new anticancer drugs.
Researchers at Sanford-Burnham Medical Research Institute have developed nanoparticles that can deliver small interfering RNA molecules to specific cells, effectively silencing malfunctioning genes. The approach points toward new ways to treat diseases such as cancer and heart disease by using RNA interference.
Researchers have discovered genetic processes that cause specific types of bowel cancer and identified effective drugs targeting these genes. The findings offer the opportunity to develop personalized treatment based on a person's genetic profile, with promising results for alternative second- or third-line treatments.
A team of scientists at Cold Spring Harbor Laboratory has discovered a way to prevent pancreatic tumor cells from responding to chemotherapy. The antibody FG-3019 targets survival cues inside the tumor mass, increasing the effectiveness of treatment and reducing drug resistance.
Scientists have developed a roadmap for ATP-binding cassette (ABC) transporter proteins, crucial components of every cell that are involved in tumor resistance and disease. Understanding how these proteins interact with other vital components can help develop targeted drugs to treat diseases such as cystic fibrosis, cancer, and others.
A new study has revealed that the COX-2 enzyme is largely absent from major blood vessels, instead found in brain, kidney, thymus, and gut. This knowledge paves the way for the development of safer, more targeted drugs for arthritis patients with fewer side effects.
Researchers at ETH Zurich developed a new PET tracer that targets the folic acid receptor on cancer cells, enabling precise diagnosis and predicting patient response to therapy. The tracer also has potential for displaying inflammatory diseases and medication development.
A new treatment approach using MGN1703, a small DNA molecule that stimulates the immune system, has shown promise in prolonging progression-free survival in patients with metastatic colorectal cancer. The drug is designed to broadly activate all components of the innate immune system to destroy cancer cells.
A phase III trial found that adding chemotherapy to surgery after curative D2 gastrectomy improved 5-year survival by 34% compared to surgery alone. The study, CLASSIC, added combination chemotherapy (XELOX) to standard treatment, showing a significant reduction in cancer-related death.
A new study by RI-MUHC researchers identifies a previously unknown mode of cancer progression, where infection-fighting white blood cells activate cancer cells and facilitate their spread to secondary tumours. Medications already used for other non-cancer diseases may prevent this mechanism of cancer spread or metastasis.
The foundation awarded six new Clinical Investigators, including Omar Abdel-Wahab and Himisha Beltran, for their cancer research programs. The recipients will receive $450,000 each, while three others received Continuation Grants worth $300,000 to support ongoing research.
Researchers at USC Norris Comprehensive Cancer Center have discovered a promising new way to treat primary effusion lymphoma (PEL), a rare and aggressive blood cancer often found in people with HIV. BRD4 inhibitors show effectiveness against PEL, which has a poor prognosis, offering hope for new therapies.
The USPSTF recommends screening for hepatitis C virus (HCV) infection in persons at high risk for infection. One-time screening for all adults born between 1945 and 1965 may identify infected patients at an earlier, more treatable stage of disease.
A Stanford-led study found that men diagnosed with azoospermia have a significantly higher risk of developing cancer than the general population. The study, which analyzed data from over 2,200 infertile men, found that azoospermic men were nearly three times more likely to receive a cancer diagnosis than non-azoospermic men.
Researchers at Scripps Research Institute receive $1.4 million from the National Cancer Institute to create a potential new drug targeting malignant cells in CLL, while sparing normal tissues. The study aims to deliver cytotoxic drugs with specific targeting using cell surface receptor TOSO and receptor tyrosine kinase ROR1.
Harvard researchers have identified the SALL4 gene as a key player in tumor formation, and have demonstrated that blocking its activity can halt cancer growth. The study provides new hope for treating aggressive forms of leukemia and other cancers.
A new drug called pyrvinium pamoate inhibits aggressive prostate cancer resistant to standard drugs by binding to a different site on the AR and inhibiting its activity without preventing androgen binding. This unique mechanism of action has the potential to treat cancers resistant to currently approved therapies.
Researchers at Northwestern University have found a molecular pathway that prevents the death of immature ovarian eggs due to chemotherapy, potentially preserving fertility and endocrine function. Adding a specific chemotherapy drug combination may protect young women's reproductive health during cancer treatment.
A study shows that bazedoxifene, an approved osteoporosis drug, inhibits estrogen-induced gene expression and cell proliferation in breast cancer cells. The medication also reduced estrogen activity and estrogen receptor levels in cultured human breast cancer cells.
Researchers have found that bazedoxifene can stop the growth of breast cancer cells, including those with resistance to current targeted therapies. The study suggests that bazedoxifene's unique mechanism of action may make it a viable treatment option for patients with advanced breast cancer.
Researchers found that a developmental protein called ROR1 promotes cancer metastasis by regulating epithelial-mesenchymal transition. Silencing ROR1 reverses this process and inhibits tumor growth in animal models.
The Society of Interventional Radiology has selected 18 new Fellows who have demonstrated excellence in research and publishing or teaching and leadership within the field. These individuals will play key roles in advancing the science and technology of interventional radiology.
Researchers identified two gene variants that can predict which women are most likely to benefit from breast cancer prevention treatment and which should avoid it. The study found that women with the beneficial version of the two SNPs were 5.71 times less likely to develop breast cancer while taking preventive drugs.
Researchers used nanosensors and advanced imaging techniques to track the spread of pancreatic tumors and monitor the effectiveness of drugs. The study reveals promising results for combination therapies that can enhance drug delivery and improve clinical outcomes.
Researchers found that none of the 169 cancer clinical practice guidelines met all eight criteria set by the Institute of Medicine. However, some guidelines were rated as 'good,' highlighting the need for a balance between ideal standards and practical implementation.
A study found that rod-shaped nanoparticles adhere effectively to endothelial cells, enhancing drug delivery. Researchers believe this technology holds promise for novel targeted therapies with fewer side effects.
ACS honors Stephen J. Lippard, Ph.D. for his groundbreaking work in inorganic chemistry, paving the way for improvements in human health and cancer treatment.
Researchers developed a new treatment combining chemotherapy and radioimmunotherapy, which showed significant improvement in survival rates without recurrence. Patients who received this treatment had a 64% chance of survival and a 100% chance of survival at two-year follow-up.
A joint investigation by BMJ and Channel 4 Dispatches found that evidence of potential harm from new diabetes drugs has not been fully published. This has led to millions of patients worldwide being under-informed about possible risks. Regulators in Europe and the US have faced criticism for their slow response to emerging concerns.
Researchers identified novel FGFR gene fusions across various cancer types, suggesting potential therapeutic targets for patients. The study's findings have the potential to identify actionable mutations that can be treated with precision therapies.
Recent data suggest that aspirin reduces heart attacks, but also increases risk of gastrointestinal bleeding and stroke. The study found that including a cancer mortality benefit influences aspirin prescribing thresholds, making middle-aged men eligible for prevention.
Researchers Brian Druker and Charles Sawyers developed imatinib, a widely used drug targeting cancer cells, transforming chronic myeloid leukemia from fatal to manageable. Their work inspired the pharmaceutical industry and future physician-scientists.
A new study released by George Mason University researchers has shown success in pinpointing individualized treatment for women with metastatic breast cancer. The pilot study combined proteomic and genomic research, achieving a 30% increase in progression-free survival for nearly half of the patients.